Compounds > fingolimod hydrochloride
Page last updated: 2024-09-02

fingolimod hydrochloride and Cancer of Prostate

fingolimod hydrochloride has been researched along with Cancer of Prostate in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's4 (36.36)29.6817
2010's6 (54.55)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abdel-Naim, AB; Al-Abd, AM; Allam, RM; Khalifa, AE; Khedr, A; Mosli, HA; Nofal, SM; Sharaf, OA1
Cristóbal, I; Daoud, L; García-Foncillas, J; González-Alonso, P; Madoz-Gúrpide, J; Manso, R; Rojo, F; Solano, E; Torrejón, B1
Chan, KW; Chiu, YT; Chua, CW; Ling, MT; Man, K; Wang, X; Wong, YC; Yuen, HF1
Bittman, R; Lim, KG; Long, J; Loveridge, C; Pitson, SM; Pyne, NJ; Pyne, S; Tigyi, G; Tonelli, F1
Bohler, T; Brizuela, L; Cuvillier, O; Doumerc, N; Golzio, M; Malavaud, B; Pchejetski, D; Salunkhe, V; Sauer, L; Teissié, J; Waxman, J1
Böhler, T; Pchejetski, D; Stebbing, J; Waxman, J1
Alossaimi, M; Bittman, R; Chan, E; Pyne, NJ; Pyne, S; Tate, RJ; Tonelli, F; Watson, DG; Williamson, L1
Chan, FL; Chua, CW; Ho, J; Lee, DT; Ling, MT; Man, K; Wang, X; Wong, YC; Zhou, C1
Kin-Wah Lee, T; Ling, MT; Man, K; Wang, X; Wong, YC; Zhou, C1
Azuma, H; Ichimaru, N; Matsumiya, K; Nonomura, N; Okuyama, A; Suzuki, S; Takahara, S; Toki, K; Wang, JD1
Kongkanand, A; Matsumiya, K; Nishimura, K; Nonomura, N; Okuyama, A; Permpongkosol, S; Takahara, S; Tsujimura, A; Wang, JD1

Reviews

1 review(s) available for fingolimod hydrochloride and Cancer of Prostate

ArticleYear
Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.
    Nature reviews. Urology, 2011, Sep-13, Volume: 8, Issue:10

    Topics: Animals; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Male; Mice; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Prostatic Neoplasms; Signal Transduction; Sphingosine

2011

Other Studies

10 other study(ies) available for fingolimod hydrochloride and Cancer of Prostate

ArticleYear
Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells.
    Toxicology letters, 2018, Volume: 291

    Topics: Antineoplastic Agents; Apoptosis; Catechol O-Methyltransferase; Catechols; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Estrogens; Fingolimod Hydrochloride; Humans; Male; Prostatic Neoplasms; Receptor Cross-Talk; Receptors, Estrogen; Sphingolipids; Tumor Microenvironment

2018
Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer.
    Marine drugs, 2015, May-27, Volume: 13, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colforsin; Fingolimod Hydrochloride; Humans; Male; Molecular Targeted Therapy; Okadaic Acid; Phosphorylation; Prostatic Neoplasms; Protein Phosphatase 2

2015
Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jul-01, Volume: 15, Issue:13

    Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Case-Control Studies; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Propylene Glycols; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Sphingosine; Tumor Cells, Cultured

2009
FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells.
    Cellular signalling, 2010, Volume: 22, Issue:10

    Topics: Androgens; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fingolimod Hydrochloride; Humans; Male; Muscle, Smooth, Vascular; Organophosphonates; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Pulmonary Artery; Sphingosine; Stereoisomerism; Vinyl Compounds

2010
FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.
    Cancer research, 2010, Nov-01, Volume: 70, Issue:21

    Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Fingolimod Hydrochloride; Flow Cytometry; Gamma Rays; Humans; Immunosuppressive Agents; Male; Mice; Mice, Nude; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Prostatic Neoplasms; Radiation Tolerance; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sphingosine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2010
The sphingosine kinase inhibitor 2-(p-hyroxyanilino)-4-(p-chlorophenyl)thiazole reduces androgen receptor expression via an oxidative stress-dependent mechanism.
    British journal of pharmacology, 2013, Volume: 168, Issue:6

    Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; Enzyme Inhibitors; Fingolimod Hydrochloride; Free Radical Scavengers; Humans; Isoenzymes; Male; Neoplasm Proteins; Oxidative Stress; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Processing, Post-Translational; Protein Stability; Receptors, Androgen; RNA, Messenger; Sphingosine; Thiazoles

2013
FTY720, a fungus metabolite, inhibits in vivo growth of androgen-independent prostate cancer.
    International journal of cancer, 2005, Dec-20, Volume: 117, Issue:6

    Topics: Androgens; Animals; Apoptosis; beta Catenin; Body Weight; Cadherins; Caspase 3; Caspases; Cell Division; Fingolimod Hydrochloride; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Orchiectomy; Platelet Endothelial Cell Adhesion Molecule-1; Propylene Glycols; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Sphingosine; Vascular Endothelial Growth Factor A

2005
FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase.
    Cancer letters, 2006, Feb-20, Volume: 233, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cytoskeleton; Fingolimod Hydrochloride; Humans; Male; Neoplasm Invasiveness; Propylene Glycols; Prostatic Neoplasms; rhoA GTP-Binding Protein; Sphingosine

2006
Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation.
    The Prostate, 1999, Jun-15, Volume: 40, Issue:1

    Topics: Androgens; Apoptosis; Caspase 3; Caspases; Fingolimod Hydrochloride; Humans; Male; Propylene Glycols; Prostatic Neoplasms; Sphingosine; Tumor Cells, Cultured

1999
Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis.
    International journal of cancer, 2002, Mar-10, Volume: 98, Issue:2

    Topics: Adenocarcinoma; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Cycle; Cell Cycle Proteins; Cysteine Proteinase Inhibitors; Enzyme Inhibitors; Fingolimod Hydrochloride; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Kinetics; Male; MAP Kinase Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Mitogens; p38 Mitogen-Activated Protein Kinases; Propylene Glycols; Prostatic Neoplasms; Protein-Tyrosine Kinases; Signal Transduction; Sphingosine; Tumor Cells, Cultured

2002